Last reviewed · How we verify
S-1 and cisplatin
S-1 is a combination of three components that inhibit thymidylate synthase and other enzymes in the pyrimidine synthesis pathway, while cisplatin is a platinum-based alkylating agent that cross-links DNA, together producing synergistic cytotoxic effects against cancer cells.
S-1 is a combination of three components that inhibit thymidylate synthase and other enzymes in the pyrimidine synthesis pathway, while cisplatin is a platinum-based alkylating agent that cross-links DNA, together producing synergistic cytotoxic effects against cancer cells. Used for Gastric cancer (advanced or metastatic), Gastroesophageal junction cancer.
At a glance
| Generic name | S-1 and cisplatin |
|---|---|
| Also known as | TS-1 and cisplatin |
| Sponsor | Asan Medical Center |
| Drug class | Fluoropyrimidine antimetabolite + platinum-based alkylating agent |
| Target | Thymidylate synthase (S-1); DNA (cisplatin) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
S-1 (tegafur, gimeracil, oteracil potassium) is an oral fluoropyrimidine prodrug that inhibits thymidylate synthase and other nucleotide synthesis enzymes, disrupting DNA replication. Cisplatin covalently binds to DNA, forming interstrand and intrastrand cross-links that prevent DNA replication and transcription. The combination exploits complementary mechanisms of action to enhance cytotoxic activity against rapidly dividing tumor cells.
Approved indications
- Gastric cancer (advanced or metastatic)
- Gastroesophageal junction cancer
Common side effects
- Myelosuppression (neutropenia, thrombocytopenia)
- Nausea and vomiting
- Diarrhea
- Anemia
- Nephrotoxicity
- Peripheral neuropathy
- Mucositis
Key clinical trials
- Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs) (PHASE3)
- Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01) (PHASE3)
- Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma (PHASE2)
- Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811) (PHASE3)
- A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma (PHASE2)
- A Benefit Population Atlas of nICT Versus nCT for LAGC
- Watch-and-Wait After Immunochemotherapy in Locally Recurrent Nasopharyngeal Carcinoma
- Iparomlimab/Tuvorlimab (QL1706) and Modified TPF Regimen for Induction Therapy in LANPC (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- S-1 and cisplatin CI brief — competitive landscape report
- S-1 and cisplatin updates RSS · CI watch RSS
- Asan Medical Center portfolio CI